Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT-Reference-Cited by-同舟云学术

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT

Published:2023-01 Issue:1 Volume:10 Page:e59-e70
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Polverelli Nicola,Hernández-Boluda Juan Carlos,Czerw Tomasz,Barbui Tiziano,D'Adda Mariella,Deeg Hans Joachim,Ditschkowski Markus,Harrison Claire,Kröger Nicolaus Martin,Mesa Ruben,Passamonti Francesco,Palandri Francesca,Pemmaraju Naveen,Popat Uday,Rondelli Damiano,Vannucchi Alessandro Maria,Verstovsek Srdan,Robin Marie,Colecchia Antonio,Grazioli Luigi,Damiani Enrico,Russo Domenico,Brady Jessica,Patch David,Blamek Slawomir,Damaj Gandhi Laurent,Hayden Patrick,McLornan Donal P,Yakoub-Agha Ibrahim

Publisher

Elsevier BV

Subject

Hematology

Reference76 articles.

1. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients;Polverelli;Hematol Oncol,2018

2. Second primary malignancy in myelofibrosis patients treated with ruxolitinib;Polverelli;Br J Haematol,2021

3. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

4. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type;Bacigalupo;Bone Marrow Transplant,2010

5. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Stem Cell Transplantation for Myelofibrosis;Current Hematologic Malignancy Reports;2024-09-06

2. Importance of allogeneic stem cell transplantation in myelofibrosis;memo - Magazine of European Medical Oncology;2024-08-12

3. Impact of post-transplant cyclophosphamide and splenomegaly on primary graft failure and multi-lineage cytopenia after allogeneic hematopoietic cell transplantation;Leukemia Research;2024-08

4. Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib;Clinical Lymphoma Myeloma and Leukemia;2024-07

5. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT;American Journal of Hematology;2024-02-22